Among the core assets that Gilead (Nasdaq: GILD) acquired from Myogen in 2006 for $2.5B was Letairis® (ambrisentan), for the treatment of pulmonary arterial hypertension (PAH), which was then approved by the FDA in mid 2007. After about a quarter in the market Gilead has initiated a Phase IV, randomized, double-blind, placebo-controlled study evaluating Letairis® [...]

• 386http://clsdf.com/2008/05/off-to-phase-iv-for-letairis%c2%ae-and-the-market-for-volibris%c2%ae/Off+to+Phase+IV+for+Letairis%C2%AE+and+the+Market+for+Volibris%C2%AE2008-05-02+15%3A01%3A00admin

Congratulations to Michael Bristow, M.D., Ph.D., the S. Gilbert Blount Professor of Medicine at University of Colorado, Head of Cardiology, Co-director of the University of Colorado Cardiovascular Institute, co-founder of Myogen (acquired by Gilead (NASDAQ: GILD), founder of ARCA Discovery and now add to that list winner of the Pharmaceutical Research and Manufacturers of America [...]

• 333http://clsdf.com/2008/02/michael-bristow-m-d-ph-d-wins-2008-phrma-award/Michael+Bristow%2C+M.D.%2C+Ph.D.+Wins+2008+PhRMA+Award2008-02-29+14%3A28%3A00admin